helpline 01494 601 400


Cannabis-based drug shows promise in severe epilepsy

Two sample bottles containing the cannabis plant used to develop a potential  new treatment for severe epilepsy.

Latest trial into the use of a cannabis-based drug for the treatment of a highly drug-resistant form of epilepsy shows positive results.

GW Pharmaceuticals begins phase 3 Epidiolex study in tuberous sclerosis complex

GW Pharmaceuticals has announced the start of a Phase 3 clinical trial of Epidiolex® (a cannabidiol-based medication) as an adjunctive therapy for the treatment of epileptic seizures in the rare genetic disorder tuberous sclerosis complex (TSC).

Cannabis-based epilepsy drug could soon be available on prescription in US

Epilepsy Society's medical director Professor Ley Sander  welcomes the latest results from the first placebo-controlled trial into the cannabis-based drug Epidiolex.

Latest cannabis trials show promise

US-based study show that a cannabis-based treatment may have the potential to reduce seizure frequency in children and young adults with highly resistant epilepsy.

Subscribe to RSS - Epidiolex